Skip to main content

Advertisement

SpringerLink
Log in

Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background and objectives

Aberrant DNA methylation contributes to the malignant phenotype in virtually all types of human cancer. This study explored the relationship between promoter methylation and inactivation of the DAPK1, FHIT, MGMT, and CDKN2A genes in cervical cancer.

Methods

The promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A was investigated by using a methylation-specific polymerase chain reaction in 53 specimens of cervical cancer (42 squamous cell carcinoma, 11 adenocarcinoma), 22 specimens of intraepithelial neoplasia tissues, and 24 control normal cervical tissue specimens. The correlation of promoter methylation with the clinicopathological features of cervical cancer was analyzed. The expressions of DAPK1, FHIT, MGMT, and CDKN2A were detected by measuring relative mRNA levels.

Results

The promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A in cervical cancer vs. intraepithelial neoplasia vs. normal cervical tissue was 75.5 vs. 31.8 vs. 4.2 % (p < 0.0001), 66.0 vs. 59.1 vs. 25.0 % (p = 0.0033), 34.0 vs. 27.3 vs. 20.8 % (p = 0.76), and 17.0 vs. 31.8 vs. 8.3 % (p = 0.11), respectively. The methylation of the promoter region significantly decreased the expression of only DAPK1 (p = 0.03). The methylation rate of the DAPK1 gene promoter was significantly higher in cervical cancer tissues than in cervical intraepithelial neoplasia and normal cervical tissues.

Conclusion

Promoter methylation may therefore lead to the inactivation of the DAPK1 gene, and may be related to the progression of cervical oncogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Center for Cancer Control and Information Services, National Cancer Center, Japan. http://ganjohojp/professional/statistics/statisticshtml

  2. Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19

    Article  CAS  PubMed  Google Scholar 

  3. Schiffman MH, Castle P (2003) Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 95:E2

    Article  PubMed  Google Scholar 

  4. Bosch FX, Manos MM, Munoz N et al (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 87:796–802

    Article  CAS  PubMed  Google Scholar 

  5. Waggoner SE (2003) Cervical cancer. Lancet 361:2217–2225

    Article  PubMed  Google Scholar 

  6. Holowaty P, Miller AB, Rohan T et al (1999) Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91:252–258

    Article  CAS  PubMed  Google Scholar 

  7. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428

    Article  CAS  PubMed  Google Scholar 

  8. Baldwin RL, Nemet E, Tran H et al (2004) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60:5329–5333

    Google Scholar 

  9. Salvesen HB, Macdonald N, Ryan A et al (2001) PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91:22–26

    Google Scholar 

  10. Zyaman M, Saka A, Millar A et al (2002) Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype. Cancer Res 62:3663–3666

    Google Scholar 

  11. Yang HJ, Lin VWS, Wang Y et al (2004) Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol 93:435–440

    Article  CAS  PubMed  Google Scholar 

  12. Dimitrios I, Pangona O, Ioannis M et al (2009) Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression. Oncol Rep 22:199–204

    Google Scholar 

  13. Zhao XL, Meng ZY, Qiao YH et al (2008) Promoter methylation of DAPK gene in cervical carcinoma. Chin J Cancer 27(9):212–215

    Google Scholar 

  14. Dong SM, Kim HS, Rha SH et al (2001) Promoter methylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7:1982–1986

    CAS  PubMed  Google Scholar 

  15. Virmani AK, Muller C, Rathi A et al (2001) Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 7:584–589

    CAS  PubMed  Google Scholar 

  16. Narayan G, Arias-Pulido H, Koul S et al (2003) Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2:24

    Article  PubMed Central  PubMed  Google Scholar 

  17. Jeong DH, Youm MY, Kin YN et al (2006) Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int J Gynecol Cancer 16:1234–1240

    Article  CAS  PubMed  Google Scholar 

  18. Widschwendter A, Gattringer C, Ivarsson L et al (2004) Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res 10:3396–3400

    Article  CAS  PubMed  Google Scholar 

  19. Lea JS, Coleman R, Kurien A et al (2004) Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol 190:674–679

    Article  CAS  PubMed  Google Scholar 

  20. Wong YF, Chung TK, Cheung TH et al (1999) Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett 136:231–235

    Article  CAS  PubMed  Google Scholar 

  21. Widschwendter A, Muller HM, Fiegl H et al (2004) DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 10:565–571

    Article  CAS  PubMed  Google Scholar 

  22. Ivanova T, Vinokurova S, Petrenko A et al (2004) Frequent methylation of 5′ flanking region of TIMP-2 gene in cervical cancer. Int J Cancer 108:882–886

    Article  CAS  PubMed  Google Scholar 

  23. Widschwendter A, Ivarsson L, Blassnig A et al (2004) CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer 109:163–166

    Article  CAS  PubMed  Google Scholar 

  24. Michie AM, McCaig AM, Nakagawa R et al (2010) Death-associated protein kinase (DAPK) and signal transduction: regulation in cancer. FEBS J 277:74–80

    Article  CAS  PubMed  Google Scholar 

  25. Ki KD, Lee SK, Tong SY et al (2008) Role of 5′-CpG island hypermethylation of the FHIT gene in cervical carcinoma. J Gynecol Oncol 19(2):117–122

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Baylin SB, Herman JG, Graff JR et al (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196

    Article  CAS  PubMed  Google Scholar 

  27. Jones PA, Laird PW (1999) Cancer epigenetic comes of age. Nat Genet 21:163–167

    Article  CAS  PubMed  Google Scholar 

  28. Lea JS, Coleman R, Kurien A et al (2004) Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol 190:674–679

    Google Scholar 

  29. Onuki M et al (2009) Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 100(7):1312–1316

    Article  CAS  PubMed  Google Scholar 

  30. Lin Z, Gao M, Zhang X et al (2005) The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions. J Cancer Res Clin Oncol 131(6):364–370

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors do not have any conflict of interests.

Author information

Authors and Affiliations

  1. Division of Obstetrics and Gynecology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Chuo Ward, Niigata, 951-8510, Japan

    Chiaki Banzai, Koji Nishino, Jinhua Quan, Kosuke Yoshihara, Masayuki Sekine, Tetsuro Yahata & Kenichi Tanaka

Authors
  1. Chiaki Banzai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koji Nishino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jinhua Quan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kosuke Yoshihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masayuki Sekine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tetsuro Yahata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenichi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Gynecological Cancer Registry of Niigata

Corresponding author

Correspondence to Chiaki Banzai.

About this article

Cite this article

Banzai, C., Nishino, K., Quan, J. et al. Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma. Int J Clin Oncol 19, 127–132 (2014). https://doi.org/10.1007/s10147-013-0530-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-013-0530-0

Keywords

Search

Navigation